Clinical trial · Observational
Respiratory Function of Dexmedetomidine in Patients Undergoing Pleuroscopy
The Effect on Respiratory Function of Monitored Anesthesia Care With Dexmedetomidine in Patients Undergoing Diagnostic or Therapeutic Pleuroscopy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this prospective trial will be to assess the effects of dexmedetomidine administration on oxygenation and respiratory function in patients undergoing diagnostic or therapeutic medical thoracoscopy/pleuroscopy for a pleural effusion compared to conventional conscious sedation/monitored anesthesia care (MAC) with midazolam. The secondary endpoint of the study will be to also assess the effects of dexmedetomidine administration on respiratory mechanics and postprocedural complications
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pleural Diseases | — | UNRESOLVED | — |
| Pleural Effusion, Malignant | — | UNRESOLVED | — |
| Pleural Effusions, Chronic | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- DEXMEDETOMIDINE
- description
- Dexmedetomidine infusion for pleuroscopy sedation. Rescue drugs will be midazolam for inadequate sedation and fentanyl for pain control
- label
- MIDAZOLAM/FENTANYL
- description
- Midazolam for sedation and fentanyl for pain will be used for pleuroscopy monitored anesthesia care
Primary outcomes (1)
- measure
- PaO2/FIO2 ratio
- timeFrame
- measured before procedure, every 30 minutes during procedure, before discharge from the postanesthesia care unit (approximately 2 hours after end of procedure)
- description
- changes in lung oxygenation
Secondary outcomes (4)
- measure
- FEV1 (forced expiratory volume in 1 second)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years old * American Society of Anesthesiologists (ASA) physical status of I-IV * scheduled to undergo medical thoracoscopy/pleuroscopy. Exclusion Criteria: * general anesthesia within 7 days prior to study entry * received an α2-agonist or antagonist within 14 days before the procedure * received an intravenous opioid within 1 hour * received an oral or intramuscular opioid within 4 hours from procedure * New York Heart Association class ≥3 * acute unstable angina * acute myocardial infarction (confirmed by laboratory findings) in the past 6 weeks * heart rate (HR) ≤45-50 bpm * systolic blood pressure (SBP) ≤90 mm Hg, * 2nd or/and 3rd-degree Atrioventricular (AV) block (if the patient does not have a pacemaker) * severe functional liver or kidney disease, * obesity (body mass index ≥30 kg/m-2) * severe restrictive interstitial lung disease
References
Publications (0)
Data not yet available